XELOX-1/NO16966, a randomized phase III trial of first-line XELOX vs. FOLFOX-4 for patients with metastatic colorectal cancer (MCRC): Updated overall survival.
BOPA 2009 Clinical Update: Colorectal Cancer Dr Nick Maisey.
BOPA 2009